Design, Synthesis, Pharmacological Evaluation of Quinazolin-4(3H)-Ones Bearing Urea Functionality as Potential VEGFR-2 Inhibitors

Background: In response to the urgent need for continuous discovery of new anti-proliferative agents, a new series of quinazoline
compounds 5a-r was prepared.
Methods: As a reference, four cancer cell lines—HCT116, HePG2, Hela, and MCF-7—and sorafenib (SOR) were used to assess the
novel motifs’ in vitro anticancer efficacy. The most cytotoxic compounds were tested in a VEGFR-2 suppressive test and flow
cytometric test. Docking analysis was done to the three novel motifs.
Results: Compound 5d showed the best anti-tumor activity of the tested compounds with IC50 6.09, 2.39, 8.94 and 4.81 μM in
succession. In addition, compound 5h revealed a potent anticancer effect against HCT116 and HePG2 with IC50 5.89 and 6.74 μM,
respectively. Also, compound 5p exhibited very strong activity against HCT116, HePG2 & MCF7 with IC50 8.32, 9.72 and 7.99,
respectively. Compound 5p had the highest inhibition against VEGFR-2 with an IC50 of 0.117 μM, in contrast to 0.069 μM for SOR.
According to flow cytometric testing, the most effective VEGFR-2 inhibitory agent, 5p, was shown to suppress the G1/S cell
population in MCF-7 cells. Docking analysis confirmed that the three novel motifs could bind to the VEGFR-2 enzyme’s binding
region like the co-crystallized ligand SOR did.
Conclusion: The enzyme inhibitory test of compound 5p showed that it is the most potent hybrid that caused MCF-7 cells to undergo
apoptosis and generated a G1/S cell cycle arrest. Confirmation of the obtained results was done with the aid of the docking study,
which showed that the three motifs might adhere to the enzyme’s major active sites, and the results were in good accordance with the
experimental VEGFR-2 inhibitory results. We can conclude that the new quinazoline compounds 5a-r could be used as candidates for
development of more efficient anticancer inhibitors.